EGFR and neoplasm: A companion diagnostic test to detect epidermal growth factor receptor (EGFR) mutations in the circulating tumor DNA (ctDNA) of patients with non-small cell lung cancer (NSCLC) who may benefit from targeted therapy with erlotinib and osimertinib [16].